JP2018516937A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516937A5
JP2018516937A5 JP2017562994A JP2017562994A JP2018516937A5 JP 2018516937 A5 JP2018516937 A5 JP 2018516937A5 JP 2017562994 A JP2017562994 A JP 2017562994A JP 2017562994 A JP2017562994 A JP 2017562994A JP 2018516937 A5 JP2018516937 A5 JP 2018516937A5
Authority
JP
Japan
Prior art keywords
pain
composition
item
eudragit
constipation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017562994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/035886 external-priority patent/WO2016197042A1/en
Publication of JP2018516937A publication Critical patent/JP2018516937A/ja
Publication of JP2018516937A5 publication Critical patent/JP2018516937A5/ja
Pending legal-status Critical Current

Links

JP2017562994A 2015-06-05 2016-06-03 リナクロチドの改変または標的放出製剤 Pending JP2018516937A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562171462P 2015-06-05 2015-06-05
US62/171,462 2015-06-05
US201662339462P 2016-05-20 2016-05-20
US62/339,462 2016-05-20
PCT/US2016/035886 WO2016197042A1 (en) 2015-06-05 2016-06-03 Modified or targeted release formulations of linaclotide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020166911A Division JP2021001223A (ja) 2015-06-05 2020-10-01 リナクロチドの改変または標的放出製剤

Publications (2)

Publication Number Publication Date
JP2018516937A JP2018516937A (ja) 2018-06-28
JP2018516937A5 true JP2018516937A5 (https=) 2019-07-04

Family

ID=56133109

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017562994A Pending JP2018516937A (ja) 2015-06-05 2016-06-03 リナクロチドの改変または標的放出製剤
JP2020166911A Withdrawn JP2021001223A (ja) 2015-06-05 2020-10-01 リナクロチドの改変または標的放出製剤
JP2022164508A Withdrawn JP2022179727A (ja) 2015-06-05 2022-10-13 リナクロチドの改変または標的放出製剤
JP2024140831A Pending JP2024161048A (ja) 2015-06-05 2024-08-22 リナクロチドの改変または標的放出製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020166911A Withdrawn JP2021001223A (ja) 2015-06-05 2020-10-01 リナクロチドの改変または標的放出製剤
JP2022164508A Withdrawn JP2022179727A (ja) 2015-06-05 2022-10-13 リナクロチドの改変または標的放出製剤
JP2024140831A Pending JP2024161048A (ja) 2015-06-05 2024-08-22 リナクロチドの改変または標的放出製剤

Country Status (5)

Country Link
US (2) US20190350863A1 (https=)
EP (1) EP3302440B1 (https=)
JP (4) JP2018516937A (https=)
ES (1) ES2868873T3 (https=)
WO (1) WO2016197042A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47112A (fr) * 2016-12-21 2019-10-30 Ironwood Pharmaceuticals Inc Procédés de traitement du syndrome du côlon irritable avec des formulations à libération modifiée ou retardée de linaclotide
US20220241367A1 (en) * 2019-06-10 2022-08-04 Ironwood Pharmaceutical, Inc. Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome
JP7599014B2 (ja) * 2020-06-30 2024-12-12 オクヴィルク，ゼレン グアニル酸シクラーゼｃ（ｇｕｃｙ２ｃ）アゴニストおよび短鎖脂肪酸またはそのプロドラッグの組み合わせを含む医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117530912A (zh) * 2008-08-15 2024-02-09 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
CA2994066A1 (en) * 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
DK2603232T3 (da) * 2010-08-11 2019-12-09 Ironwood Pharmaceuticals Inc Stabile formuleringer af linaclotid
JP5553132B2 (ja) * 2011-09-30 2014-07-16 アステラス製薬株式会社 粒子状医薬組成物
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням

Similar Documents

Publication Publication Date Title
KR101799625B1 (ko) 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물
KR101799624B1 (ko) 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물
El-Zahaby et al. Formulation and in vitro evaluation of size expanding gastro-retentive systems of levofloxacin hemihydrate
CA2984434C (en) Monolithic tablets based on carboxyl polymeric complexes for controlled drug release
KR101767288B1 (ko) 복용 용이성 고형 제제
JP2017504590A5 (https=)
JP2013522373A (ja) 高用量、水溶性及び吸湿性薬剤基質用の制御放出性剤形
HRP20231699T1 (hr) Formulacije inhibitora amorfne kinaze i postupci njihove primjene
JP6768070B2 (ja) 粘膜付着性医薬組成物及びその製造方法
CN103269691A (zh) 用于控制释放美沙拉嗪的口服药物片剂和其获得方法
CN105025888B (zh) 肠溶片
WO2017022248A1 (ja) 腸溶性カプセル
JP2018516937A5 (https=)
Ramli et al. Coatless alginate pellets as sustained-release drug carrier for inflammatory bowel disease treatment
Segale et al. Calcium alginate multi-unit oral dosage form for delayed release of celecoxib
KR102298473B1 (ko) 제어 방출 제약 투여 형태
CN110475557B (zh) 固体分散体
Newton et al. Effect of HPMC-E15 LV premium polymer on release profile and compression characteristics of chitosan/pectin colon targeted mesalamine matrix tablets and in vitro study on effect of pH impact on the drug release profile
CA2833115C (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
CN118234489A (zh) 吡啶酮衍生物的口服制剂及其在肠纤维化的预防和/或治疗中的用途
Tiwari et al. Enhancement of site specific delivery of diloxanide furoate as an antiamoebic drug
CA3060026A1 (en) Polymer based formulation for release of drugs and bioactives at specific git sites
Elghamry et al. Formulation and evaluation of colon targeted pulsincap delivery of Carvedilol for treatment of hypertension
Raffin et al. Pantoprazole sodium-loaded controlled release microparticles prepared by spray drying
Kopanar et al. COLON DRUG DELIVERY OF BERBERIN HYDROCHLORIDE